Please assess the completion status of the following clinical trial:

Trial Title: A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria~* PAH belonging to one of the subgroups:~  1. I/HPAH, PAH-CTD,~ 2. PAH due to drugs and/or toxins/chemicals (having been in the care of the investigator for at least one year with no relapses of drug or toxin/chemical abuse),~ 3. HIV associated or~ 4. PAH due to repaired congenital heart disease (at least 1 year since repair)~* World Health Organization (WHO) Functional Class II, III or IV symptoms~* Stable concomitant background therapy of at least one PAH approved medications~* Able to walk a distance of at least 100 m but no more than 475 m during the Screening 6-minute walk tests.~Key Exclusion Criteria~* Pulmonary hypertension (PH) belonging to Groups 2 to 5~* A history of left-sided heart disease~* Pregnant or breast-feeding females~Additional criteria may apply, per protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- AV-101 10 mg (Type: EXPERIMENTAL): None
- AV-101 35 mg (Type: EXPERIMENTAL): None
- AV-101 70 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).